A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome and/or BCR-ABL Positive CML in Chronic Phase - ENEST1st

Trial Profile

A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome and/or BCR-ABL Positive CML in Chronic Phase - ENEST1st

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms ENEST1st; MACS1252
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 27 Feb 2017 Last checked against the ClinicalTrials.gov record.
    • 10 Jan 2017 Results of a sub-study (n=52) assessing immune-modulating potential of nilotinib, published in the Journal of Clinical Oncology
    • 06 Dec 2016 Results of sub-study (n=52) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top